ACEMg, brand name Soundbites, was developed at the University of Michigan Medical School. ACEMg patents are licensed by the University of Michigan to Soundbites PBC. Soundbites is a safe, novel oral otoprotectant patented for preventing and treating sensorineural hearing loss (SNHL) caused by endogenous and exogenous ototoxicity triggered by upregulated inner ear reactive oxygen species (ROS), and for preventing and treating temporary and permanent tinnitus caused the same way.
Sound or noise exposure is the main exogenous factor contributing to SNHL. Endogenous factors include genetic mutations (GJB2/Connexin 26); viruses (congenital cytomegalovirus, or cCMV); and drugs with ototoxic side effects (e.g. aminoglycoside antibiotics, or antiretroviral drug cocktails (ARV) used to treat HIV, and drugs used to treat multi-drug resistant tuberculosis (MDR TB).